Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.62
+1.4%		$248.48
$190.75
▼
$267.47
$468.13B0.35.38 million shs5.14 million shs
Mastercard Incorporated stock logo
MA
Mastercard
$580.26
+1.1%		$538.80
$464.52
▼
$601.77
$508.64B0.723.09 million shs2.20 million shs
Morgan Stanley stock logo
MS
Morgan Stanley
$214.42
+3.4%		$217.16
$144.67
▼
$232.25
$337.85B1.224.74 million shs4.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+3.43%+22.96%+27.26%
Mastercard Incorporated stock logo
MA
Mastercard
0.00%+1.97%+9.38%+16.46%-2.02%
Morgan Stanley stock logo
MS
Morgan Stanley
0.00%-1.33%-0.39%+6.58%+48.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.62
+1.4%		$248.48
$190.75
▼
$267.47
$468.13B0.35.38 million shs5.14 million shs
Mastercard Incorporated stock logo
MA
Mastercard
$580.26
+1.1%		$538.80
$464.52
▼
$601.77
$508.64B0.723.09 million shs2.20 million shs
Morgan Stanley stock logo
MS
Morgan Stanley
$214.42
+3.4%		$217.16
$144.67
▼
$232.25
$337.85B1.224.74 million shs4.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+3.43%+22.96%+27.26%
Mastercard Incorporated stock logo
MA
Mastercard
0.00%+1.97%+9.38%+16.46%-2.02%
Morgan Stanley stock logo
MS
Morgan Stanley
0.00%-1.33%-0.39%+6.58%+48.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$275.953.89% Upside
Mastercard Incorporated stock logo
MA
Mastercard
3.10
Buy$661.9314.07% Upside
Morgan Stanley stock logo
MS
Morgan Stanley
2.58
Moderate Buy$224.754.82% Upside

Current Analyst Ratings Breakdown

Latest ABBV, MS, and MA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$298.00 ➝ $303.00
8/17/2026
Mastercard Incorporated stock logo
MA
Mastercard
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/17/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$295.00 ➝ $300.00
8/13/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/11/2026
AbbVie Inc. stock logo
ABBV
AbbVie
BNP Paribas Exane logo
BNP Paribas Exane
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$218.00 ➝ $247.00
8/5/2026
Morgan Stanley stock logo
MS
Morgan Stanley
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/5/2026
Mastercard Incorporated stock logo
MA
Mastercard
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$554.00 ➝ $633.00
8/5/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank AG logo
Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
8/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Buy (B-)
8/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$261.00 ➝ $288.00
8/3/2026
Morgan Stanley stock logo
MS
Morgan Stanley
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$255.00 ➝ $260.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$64.39B7.29$15.19 per share17.49($3.33) per share-79.77
Mastercard Incorporated stock logo
MA
Mastercard
$32.79B15.50$20.86 per share27.82$6.40 per share90.67
Morgan Stanley stock logo
MS
Morgan Stanley
$119.66B2.83$13.55 per share15.82$68.28 per share3.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5475.0316.440.889.80%-422.07%14.34%10/30/2026 (Estimated)
Mastercard Incorporated stock logo
MA
Mastercard
$14.97B$18.1831.9225.341.7446.34%239.99%30.88%10/29/2026 (Estimated)
Morgan Stanley stock logo
MS
Morgan Stanley
$16.86B$12.3717.3316.421.5215.65%19.31%1.33%10/14/2026 (Estimated)

Latest ABBV, MS, and MA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/30/2026Q2 2026
Mastercard Incorporated stock logo
MA
Mastercard
$4.77$5.04+$0.27$4.97$9.08 billion$9.28 billion
7/15/2026Q2 2026
Morgan Stanley stock logo
MS
Morgan Stanley
$2.89$3.46+$0.57$3.46$19.67 billion$21.35 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.61%+6.80%195.48%53 Years
Mastercard Incorporated stock logo
MA
Mastercard
$3.480.60%+13.70%19.14%13 Years
Morgan Stanley stock logo
MS
Morgan Stanley
$4.602.15%+22.42%37.19%12 Years

Latest ABBV, MS, and MA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.83%7/15/20267/15/20268/14/2026
7/15/2026
Morgan Stanley stock logo
MS
Morgan Stanley
quarterly$1.152.18%7/31/20267/31/20268/14/2026
6/16/2026
Mastercard Incorporated stock logo
MA
Mastercard
quarterly$0.870.67%7/9/20267/9/20268/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Mastercard Incorporated stock logo
MA
Mastercard
3.96
1.06
1.06
Morgan Stanley stock logo
MS
Morgan Stanley
3.65
0.79
0.79

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Mastercard Incorporated stock logo
MA
Mastercard
97.28%
Morgan Stanley stock logo
MS
Morgan Stanley
84.19%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Mastercard Incorporated stock logo
MA
Mastercard
0.09%
Morgan Stanley stock logo
MS
Morgan Stanley
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Mastercard Incorporated stock logo
MA
Mastercard
39,800876.01 million875.22 millionOptionable
Morgan Stanley stock logo
MS
Morgan Stanley
82,9921.58 billion1.57 billionOptionable

Recent News About These Companies

Inside Morgan Stanley’s XRP Shuffle: Three New ETFs and a Much Bigger SPAC Position
 |  247wallst.comhttps://247wallst.com/investing/2026/08/23/inside-morgan-stanleys-xrp-shuffle-three-new-etfs-and-a-much-bigger-spac-position/
SBI Life Plans Investor Meeting at Morgan Stanley India Financials Event
August 23 at 7:11 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sbi-life-plans-investor-meeting-at-morgan-stanley-india-financials-event?utm_source=marketbeat.com&utm_medium=referral
LM Advisors LLC Takes $1.28 Million Position in Morgan Stanley $MS
August 23 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-lm-advisors-llc-takes-128-million-position-in-morgan-stanley-ms-2026-08-23/
4,670 Shares in Morgan Stanley $MS Purchased by Great Lakes Advisors LLC
August 23 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4670-shares-in-morgan-stanley-ms-purchased-by-great-lakes-advisors-llc-2026-08-23/
Morgan Stanley Direct Lending: High Safety Margin Despite Non-Accrual Challenges
August 22 at 10:51 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4939378-morgan-stanley-direct-lending-high-safety-margin-despite-non-accrual-challenges?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Tapestry Stock (TPR) Opinions on Recent Earnings Report
August 22 at 1:50 PM  |  quiverquant.comQ
$IR stock fell 4% this week. Here's what we see in our data.
August 22 at 1:30 PM  |  quiverquant.comQ
$NBIS stock fell 22% this week. Here's what we see in our data.
August 22 at 1:30 PM  |  quiverquant.comQ
$UNH stock fell 3% this week. Here's what we see in our data.
August 22 at 1:30 PM  |  quiverquant.comQ
$CBRS stock fell 11% this week. Here's what we see in our data.
August 22 at 1:30 PM  |  quiverquant.comQ
$SNDK stock fell 3% this week. Here's what we see in our data.
August 22 at 1:30 PM  |  quiverquant.comQ
Cipher Mining Stock (CIFR) Opinions on AI Data Center Pivot
August 22 at 10:11 AM  |  quiverquant.comQ
Morgan Stanley Direct Lending Fund: The Dividend Is Likely To Get Slashed (Rating Downgrade)
August 22 at 9:31 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4939242-morgan-stanley-direct-lending-fund-dividend-is-likely-to-get-slashed-rating-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
AI Computing Power Surges While Electricity Bottlenecks Loom, Morgan Stanley Highlights Three Beneficiary Stocks
August 22 at 8:25 AM  |  nai500.comN
Heartland Bank & Trust Co Acquires New Stake in Morgan Stanley $MS
August 22 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-heartland-bank-trust-co-acquires-new-stake-in-morgan-stanley-ms-2026-08-22/
Why Morgan Stanley Stock Rocked the Market Today
August 21 at 10:22 PM  |  fool.comhttps://www.fool.com/investing/2026/08/21/why-morgan-stanley-stock-rocked-the-market-today/
Insider Sale: Chief Technology Officer of $CBRS Sells 133,383 Shares
August 21 at 9:11 PM  |  quiverquant.comQ
Why Morgan Stanley Stock Rocked the Market Today
August 21 at 8:30 PM  |  fool.comhttps://www.fool.com/investing/2026/08/21/why-morgan-stanley-stock-rocked-the-market-today/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=e40880fc-3334-4ba9-b7bc-d89917ecacdf
Morgan Stanley Doubles Down on Gold After Breakout
August 21 at 5:20 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/commodities/articles/morgan-stanley-doubles-down-gold-201259751.html
ADM slips as investors appear to take profits after earnings-driven rally
August 21 at 1:51 PM  |  quiverquant.comQ
QQQ is up 0.5% today, on TSLA stock price movement
August 21 at 12:31 PM  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
Microsoft logo displayed on a wall-mounted plaque in a modern office lobby with glass partitions.
Microsoft Just Flipped the AI Spending Narrative Overnight
By Chris Markoch | July 30, 2026
AirJoule logo over flowing water stream, symbolizing water-from-air technology and clean water production innovation.
AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
By Thomas Hughes | July 27, 2026
AbbVie logo on a curved wall in an office lobby, with a laboratory and vials visible nearby.
AbbVie Quietly Solved Its Biggest Problem—Now What?
By Thomas Hughes | August 2, 2026
Glass office towers with glowing digital network lines overlay, symbolizing tech industry data connectivity and market activity.
Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of Truth
By Bridget Bennett | August 7, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$265.62 +3.79 (+1.45%)
As of 08/21/2026 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Mastercard stock logo

Mastercard NYSE:MA

$580.26 +6.41 (+1.12%)
As of 08/21/2026 03:58 PM Eastern

Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company offers integrated products and value-added services for account holders, merchants, financial institutions, digital partners, businesses, governments, and other organizations, such as programs that enable issuers to provide consumers with credits to defer payments; payment products and solutions that allow its customers to access funds in deposit and other accounts; prepaid programs services; and commercial credit, debit, and prepaid payment products and solutions. It also provides solutions that enable businesses or governments to make payments to businesses, including Virtual Card Number, which is generated dynamically from a physical card and leverages the credit limit of the funding account; a platform to optimize supplier payment enablement campaigns for financial institutions; and treasury intelligence platform that offers corporations with recommendations to enhance working capital performance and accelerate spend on cards. In addition, the company offers Mastercard Send, which partners with digital messaging and payment platforms to enable consumers to send money directly within applications to other consumers; and Mastercard Cross-Border Services enables a range of payment flows through a distribution network with a single point of access to send and receive money globally through various channels, including bank accounts, mobile wallets, cards, and cash payouts. Further, it provides cyber and intelligence solutions; insights and analytics, consulting, marketing, loyalty, processing, and payment gateway solutions for e-commerce merchants; and open banking and digital identity services. The company offers payment solutions and services under the MasterCard, Maestro, and Cirrus name. Mastercard Incorporated was founded in 1966 and is headquartered in Purchase, New York.

Morgan Stanley stock logo

Morgan Stanley NYSE:MS

$214.42 +6.97 (+3.36%)
As of 08/21/2026 03:58 PM Eastern

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas